欧林生物控股股东拟减持 2021年上市股价业绩双巅峰

Core Viewpoint - Oulin Biological (688319.SH) announced a share reduction plan by its controlling shareholder, Shanghai Wushan Biotechnology Co., Ltd., which holds 72,394,330 shares, accounting for 17.83% of the total share capital. The reduction is due to funding needs and will not exceed 12,178,008 shares, representing no more than 3% of the total share capital [1] Financial Performance - Oulin Biological's revenue from 2021 to 2024 was 487.2 million, 547.5 million, 496.1 million, and 588.9 million respectively, showing fluctuations in growth [2] - The net profit attributable to the parent company for the same period was 108 million, 26.58 million, 17.56 million, and 20.76 million respectively, indicating a decline in profitability [2] - The non-recurring net profit figures were 96.66 million, 720,700, 338,800, and 1.118 million respectively, reflecting significant volatility [2] Shareholder Structure - The actual controllers of the company, Fan Shaowen and Fan Fan, control Shanghai Wushan, with Fan Shaowen holding 47.22% and Fan Fan holding 6.78% of the shares. Director Chen Aimin holds 20% of Shanghai Wushan [1] IPO and Fundraising - Oulin Biological raised a total of 400 million in its initial public offering, with a net amount of 359 million after deducting issuance costs, which was 404 million less than originally planned [4] - The funds were intended for vaccine clinical research projects and the industrialization of various vaccines [4]